Visual Impairment Due to Diabetic Macular Edema
3 clinical trials · Condition
◉ Watch Visual Impairment Due to Diabetic Macular Edema
| Record | Firm | Date |
|---|---|---|
| 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME. (NCT02878681) | Novartis Pharmaceuticals | 2016-09-01 |
| Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (NCT02258009) | Novartis Pharmaceuticals | 2015-10-01 |
| Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (NCT01131585) | Novartis Pharmaceuticals | 2010-06-01 |
Track Visual Impairment Due to Diabetic Macular Edema automatically
Every clearance here is in the API, with alerts when new ones post.